tradingview.com
Cure8 news brief
Why This Matters
A pediatric label for Omvoh could make an additional biologic option available for children with moderate-to-severe ulcerative colitis who respond to treatment. Trial results reported one-year remission among responders, which is directly relevant to families and clinicians treating pediatric UC.
Who Should Pay Attention
Pediatric patients with ulcerative colitis, parents and caregivers, pediatric gastroenterologists, clinicians managing biologic therapy, and researchers interested in IBD drug development.
Study Snapshot
Story typeBusiness news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
Eli Lilly reported Phase 3 SHINE-2 results showing pediatric Week 52 clinical remission among responders to Omvoh (children 4–17; analysis focused on 6–17-year-old responders). The company plans to submit the data to regulators to seek a pediatric label expansion.
The trial was single-arm and open-label; 63 children were enrolled and safety was described as consistent with adult tolerability, with four serious adverse events judged unrelated and two discontinuations after UC flares.
This summary is based on the article text provided by the source (Seeking Alpha content republished on TradingView) and does not represent a review of a full clinical study report or regulatory filing. It reports what the company announced about the trial and its regulatory plans.
If you’re a parent or caregiver of a child with ulcerative colitis, note this is an industry press-style report about a company’s planned submission rather than independent clinical guidance. Discuss treatment options and eligibility with your child’s gastroenterologist.
Keep In Mind
The SHINE-2 study was single-arm and open-label with 63 enrolled children; the Week 52 remission rate cited applies to the subgroup who initially responded and may not reflect outcomes for all treated children. The article is a company-announcement style report republished from Seeking Alpha; it’s not an independent peer-reviewed publication or regulatory decision.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationtradingview.com
Indexed viaGoogle News
Source typeWeb article
PublishedOct 19, 2026, 11:49 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
This article reports two-year data showing that mirikizumab (Omvoh) maintained clinical and endoscopic benefit for many people with moderate–severe Crohn’s disease, and that results across Phase 3 programs also support...
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate ...
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
Subcutaneous Guselkumab Proves Efficacious for IBD in Two Studies: ASTRO and GRAVITI
These are phase 3 results showing subcutaneous guselkumab helped more people reach clinical and endoscopic goals than placebo in moderate-to-severe UC and Crohn’s disease; a fully subcutaneous option could offer more...